Kistler Tiffany Companies LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,536 shares of the biopharmaceutical company’s stock after purchasing an additional 513 shares during the quarter. Kistler Tiffany Companies LLC’s holdings in Gilead Sciences were worth $604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the last quarter. APG Asset Management N.V. raised its stake in shares of Gilead Sciences by 16.7% in the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock worth $402,319,000 after purchasing an additional 849,741 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after purchasing an additional 1,066,172 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Gilead Sciences by 26.9% in the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock worth $317,059,000 after purchasing an additional 989,400 shares during the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Stake Lifted by Kistler Tiffany Companies LLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/01/gilead-sciences-inc-gild-stake-lifted-by-kistler-tiffany-companies-llc.html.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.02 on Friday. The firm’s 50-day moving average price is $77.54 and its 200-day moving average price is $70.38. The stock has a market capitalization of $105.81 billion, a P/E ratio of 8.80 and a beta of 1.19. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.08 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.78 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

GILD has been the subject of several recent analyst reports. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 4th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research note on Monday, July 17th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target for the company. in a research note on Wednesday, June 21st. Finally, Deutsche Bank AG initiated coverage on Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target for the company. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $84.29.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,819 shares of company stock worth $36,740,240. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.